Managing Directors
Joyce Erony
Managing Director
New York, NY

Mrs. Erony joined Signet Healthcare Partners in 2006 and has more than 25 years experience as a principal in investing activities, investment banking and business development. She is currently a Director of ImpoPharma, Icon Biosciences, Kew Group and Fluxion and has been a Director of IGI Labs, Peak Surgical (acquired by Medtronic), Dow Pharmaceutical Sciences (acquired by Valeant), Anteis (azquired by Merz), Atlantis Components (acquired by AstraZeneca) , and Control Delivery Systems (acquired by Psivida).

Previously, Mrs. Erony was a strategic advisor to Alcon Labs and was a Managing Director at Citigroup responsible for the Bank’s activities in specialty pharmaceuticals and medical technologies.

James C. Gale
Managing Director
New York, NY

James Gale is the founding partner of Signet Healthcare Partners. He initiates investments and provides active management oversight to a number of the portfolio companies. He is currently the Chairman of the Board of Alpex Pharma S.A. and Teligent, Inc., and also serves on the Board of Directors of Bionpharma Inc., Chr. Olesen Synthesis A/S, CoreRx Inc, and Spepharm AG.

Prior to founding Signet Healthcare Partners, Mr. Gale was head of principal investment activities and head of investment banking for Gruntal & Co., LLC. While at Gruntal, Mr. Gale’s investment activities included Andrx Corporation, Royce Laboratories (merged with Watson Pharmaceuticals), Lifecell Corporation, Neurocrine Biosciences, and BML Pharmaceuticals (acquired by Endo Pharmaceuticals).

Prior to joining Gruntal, he originated and managed private equity investments for the Home Insurance Co., Gruntal’s parent. Earlier in his career, Mr. Gale was a senior investment banker at E.F. Hutton & Co.

Mr. Gale received his Masters of Business Administration from the University of Chicago.

Todd Sone
Managing Director
New York, NY

Mr. Sone, Managing Director, of Signet was previously an Investment Director at Joddes Limited, an investment holding company with interests in a number of healthcare companies, including Pharmascience, Paladin Labs, Medicom, and Oral Science. He was the Director of Strategic Planning at Pharmascience Inc., one of the largest privately-owned generic pharmaceutical companies in the world.

Prior to joining Pharmascience, Mr. Sone was a large-cap pharmaceutical analyst at Morgan Stanley. He started his career at Mercer Management Consulting serving clients across North America in the transportation and healthcare industries.

Mr. Sone received a Bachelor of Commerce (with High Distinction) from the University of Toronto and an MBA from The Wharton School at the University of Pennsylvania.